JP2025148452A5 - - Google Patents
Info
- Publication number
- JP2025148452A5 JP2025148452A5 JP2025116414A JP2025116414A JP2025148452A5 JP 2025148452 A5 JP2025148452 A5 JP 2025148452A5 JP 2025116414 A JP2025116414 A JP 2025116414A JP 2025116414 A JP2025116414 A JP 2025116414A JP 2025148452 A5 JP2025148452 A5 JP 2025148452A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence identity
- variable region
- chain variable
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2022/079021 | 2022-03-03 | ||
| PCT/CN2022/079021 WO2023164872A1 (en) | 2022-03-03 | 2022-03-03 | Anti-cd39 antibodies and use thereof |
| CN2022126070 | 2022-10-19 | ||
| CNPCT/CN2022/126070 | 2022-10-19 | ||
| JP2024552127A JP7712496B2 (ja) | 2022-03-03 | 2023-03-02 | 抗ｃｄ３９抗体及びその使用 |
| PCT/CN2023/079295 WO2023165561A1 (en) | 2022-03-03 | 2023-03-02 | Anti-cd39 antibodies and use thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024552127A Division JP7712496B2 (ja) | 2022-03-03 | 2023-03-02 | 抗ｃｄ３９抗体及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025148452A JP2025148452A (ja) | 2025-10-07 |
| JP2025148452A5 true JP2025148452A5 (https=) | 2026-03-06 |
Family
ID=87883061
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024552127A Active JP7712496B2 (ja) | 2022-03-03 | 2023-03-02 | 抗ｃｄ３９抗体及びその使用 |
| JP2025116414A Pending JP2025148452A (ja) | 2022-03-03 | 2025-07-10 | 抗ｃｄ３９抗体及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024552127A Active JP7712496B2 (ja) | 2022-03-03 | 2023-03-02 | 抗ｃｄ３９抗体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11970543B2 (https=) |
| EP (1) | EP4486785A1 (https=) |
| JP (2) | JP7712496B2 (https=) |
| KR (1) | KR20240156633A (https=) |
| CN (2) | CN119569881B (https=) |
| AR (1) | AR128688A1 (https=) |
| AU (1) | AU2023227964A1 (https=) |
| CA (1) | CA3253669A1 (https=) |
| CL (1) | CL2024002620A1 (https=) |
| IL (1) | IL315351A (https=) |
| MX (1) | MX2024010646A (https=) |
| TW (1) | TW202340243A (https=) |
| WO (1) | WO2023165561A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023402712A1 (en) * | 2022-12-01 | 2025-05-08 | Innate Pharma | Compositions and methods for neoadjuvant treatment in cancer comprising anti-cd39 antibodies |
| CN117986364B (zh) * | 2023-12-27 | 2025-01-21 | 华润生物医药有限公司 | 特异性结合cd39的纳米抗体及其用途 |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3153526T3 (da) * | 2008-01-31 | 2020-12-14 | Inst Nat Sante Rech Med | Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler |
| WO2012085132A1 (en) | 2010-12-22 | 2012-06-28 | Orega Biotech | Antibodies against human cd39 and use thereof |
| WO2016073845A1 (en) * | 2014-11-07 | 2016-05-12 | Igenica Biotherapeutics, Inc. | Anti-cd39 antibodies and uses thereof |
| EP3380519A1 (en) | 2015-11-23 | 2018-10-03 | Innate Pharma | Cd39 vascular isoform targeting agents |
| US20190071514A1 (en) | 2016-03-14 | 2019-03-07 | Innate Pharma | Anti-cd39 antibodies |
| EP3452092B1 (en) | 2016-05-06 | 2020-08-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (aml) |
| WO2018065552A1 (en) | 2016-10-06 | 2018-04-12 | Innate Pharma | Anti-cd39 antibodies |
| CN110382544B (zh) | 2017-03-16 | 2023-12-22 | 先天制药公司 | 用于治疗癌症的组合物和方法 |
| IL316357A (en) | 2017-07-31 | 2024-12-01 | Trishula Therapeutics Inc | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| WO2019068907A1 (en) | 2017-10-06 | 2019-04-11 | Innate Pharma | RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73 |
| SG11202002195YA (en) | 2017-11-15 | 2020-04-29 | Innate Pharma | Potentiating the effect of atp release |
| MX394121B (es) | 2018-03-14 | 2025-03-24 | Surface Oncology Inc | Anticuerpos que se unen a cd39 y sus usos |
| KR20210031694A (ko) | 2018-06-14 | 2021-03-22 | 베쓰 이스라엘 디코니스 메디칼 센터 인크 | 엑토뉴클레오티다제 억제 및 항체-매개된 표적 사이토시스를 통한 t-세포 고갈을 예방 또는 역전시키는 조성물 및 방법 |
| MX2020012107A (es) | 2018-06-18 | 2021-01-29 | Innate Pharma | Composiciones y procedimientos para el tratamiento del cancer. |
| US20230242660A1 (en) | 2019-02-21 | 2023-08-03 | Trishula Therapeutics, Inc. | Combination therapy involving anti-cd39 antibodies and anti-pd-1 or anti-pd-l1 antibodies |
| KR20220061977A (ko) | 2019-08-12 | 2022-05-13 | 퓨리노미아 바이오테크, 아이엔씨. | Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물 |
| CN112714768B (zh) * | 2019-08-27 | 2025-02-18 | 科望(苏州)生物医药科技有限公司 | 新型抗cd39抗体 |
| US20220372160A1 (en) | 2019-09-16 | 2022-11-24 | Surface Oncology, Inc. | Anti-CD39 Antibody Compositions and Methods |
| CN110407941B (zh) | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
| CN114651013B (zh) | 2019-11-05 | 2025-03-14 | 北京加科思新药研发有限公司 | 对cd39具有特异性的结合分子及其用途 |
| WO2021203058A2 (en) | 2020-04-03 | 2021-10-07 | Trishula Therapeutics, Inc. | Combination therapy involving anti-cd39 antibodies and adoptive cell therapy |
| KR20230065974A (ko) | 2020-09-10 | 2023-05-12 | 퓨리노미아 바이오테크, 아이엔씨. | NTPDase3의 표적화를 통해 항종양 면역 반응을 강화하기 위한 방법 및 조성물 |
| US20230416394A1 (en) | 2020-11-27 | 2023-12-28 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel conjugate molecules targeting cd39 and tgfbeta |
-
2023
- 2023-03-02 WO PCT/CN2023/079295 patent/WO2023165561A1/en not_active Ceased
- 2023-03-02 AU AU2023227964A patent/AU2023227964A1/en active Pending
- 2023-03-02 CN CN202411518282.4A patent/CN119569881B/zh active Active
- 2023-03-02 CA CA3253669A patent/CA3253669A1/en active Pending
- 2023-03-02 IL IL315351A patent/IL315351A/en unknown
- 2023-03-02 CN CN202380024645.6A patent/CN119173535A/zh active Pending
- 2023-03-02 US US18/177,729 patent/US11970543B2/en active Active
- 2023-03-02 KR KR1020247032745A patent/KR20240156633A/ko active Pending
- 2023-03-02 JP JP2024552127A patent/JP7712496B2/ja active Active
- 2023-03-02 MX MX2024010646A patent/MX2024010646A/es unknown
- 2023-03-02 AR ARP230100529A patent/AR128688A1/es unknown
- 2023-03-02 TW TW112107685A patent/TW202340243A/zh unknown
- 2023-03-02 EP EP23762959.7A patent/EP4486785A1/en active Pending
-
2024
- 2024-03-25 US US18/616,056 patent/US20250084178A1/en active Pending
- 2024-09-02 CL CL2024002620A patent/CL2024002620A1/es unknown
-
2025
- 2025-07-10 JP JP2025116414A patent/JP2025148452A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025148452A5 (https=) | ||
| KR102812377B1 (ko) | 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체 | |
| KR102757960B1 (ko) | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 | |
| JP2021522801A5 (https=) | ||
| KR101453462B1 (ko) | Her2에 특이적으로 결합하는 항체 | |
| JP2023525827A (ja) | 抗ｃｄ７３抗体およびその使用 | |
| JP2018538274A5 (https=) | ||
| JP2014527814A5 (https=) | ||
| JP2018500384A (ja) | 腫瘍形成を治療するための治療の組合せ | |
| JP2020527332A5 (https=) | ||
| CN114601931A (zh) | 抗-cd19抗体和布鲁顿酪氨酸激酶抑制剂的组合及其用途 | |
| JP2021533796A5 (https=) | ||
| JPWO2021247591A5 (https=) | ||
| JP2024016024A5 (https=) | ||
| EA034676B1 (ru) | Новое антитело против нетрина-1 | |
| US20250042980A1 (en) | Complement factor h antibodies | |
| US20230398229A1 (en) | Antibody drug conjugates comprising sting agonists, combinations and methods of use | |
| JP2021511387A5 (https=) | ||
| KR20240038769A (ko) | 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법 | |
| EP3362480B1 (en) | Antibody specifically binding to erbb3 and use thereof | |
| JP2024532744A (ja) | Ｔ１ｇｉｔアンタゴニスト、ｐｄ－１アンタゴニスト、及び（１又は複数の）化学療法剤を含む治療的組合せ | |
| JPWO2021173832A5 (https=) | ||
| US20220389088A1 (en) | Anti-angiopoietin-like 4 (angptl4) antibodies and methods of use | |
| HK40123344A (zh) | 一种治疗实体瘤的方法 | |
| JP2026511516A (ja) | Ａｐｉ５エピトープおよびそれに特異的に結合する抗体 |